PTC Therapeutics appoints Tuyen Ong senior vice president, head of clinical development and research
Pharma company PTC Therapeutics (Nasdaq: PTCT) has appointed Tuyen Ong as senior vice president, head of clinical development and translational research.
Dr Ong said: "I am excited by the opportunity to join PTC. The innovative science behind the novel compounds discovered and developed at PTC has produced a robust pipeline of product candidates. I look forward to advancing treatments for patients with rare and neglected diseases through PTC's novel pipeline."
Phase III trials are now underway for Translarna (ataluren) in Duchenne muscular dystrophy and cystic fibrosis, and a proof-of-concept study is being prepared for Mucopolysaccharidosis or MPS 1. PTC will shortly initiate a Phase I clinical trial of PTC596, a first-in-class, oral, potent and selective inhibitor of BMI1, which targets cancer stem cells that lead to cancer recurrence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze